Adenosine 5' – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in healthy non-smokers and patients with mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 350s Year: 2003
Effect of adenosine 5´-triphosphate (ATP) challenge vs. adenosine 5´-monophosphate (AMP) on the threshold of capsaicin-induced cough in healthy non-smokers, current smokers and patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 708s Year: 2004
PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Exhaled adenosine triphosphate (ATP) concentration is elevated in stable asthmatic patients compared to control subjects Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009
Cellular and gas exchange responses to adenosine 5‘-monophosphate (AMP) challenge in mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004
Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007
An improved bronchial provocation test with dry powder adenosine instead of nebulised adenosine monophosphate (AMP) Source: International Congress 2017 – Monitoring asthma control Year: 2017
Adenosine 5'- monophosphate and methacholine challenge testing in healthy non-smokers, healthy smokers, patients with asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 477s Year: 2003
Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease Year: 2011
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Source: Eur Respir J 2008; 32: 198-209 Year: 2008
Adenosine deaminase in the COPD pathogenesis in patients with pulmonary tuberculosis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Adenosine deaminase – adenosine pathway in hemolysis-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Airway responsiveness to methacholine (Mch), adenosine 5- monophosphate (AMP), mannitol (Man), eucapnic voluntary hyperpnea (EVH) and a sport-specific field exercise challenge (Ex) in cross country ski athletes Source: Eur Respir J 2002; 20: Suppl. 38, 410s Year: 2002
Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
A single inhaled dose of INS316 (uridine 5¢-triphosphate, UTP) enhances sputum quality for the diagnosis of lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 502s Year: 2002
Adenosine 5'-triphosphate (ATP) is detectable in exhaled breath condensate (EBC) of healthy subjects Source: Eur Respir J 2003; 22: Suppl. 45, 18s Year: 2003
Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Serum adenosine deaminase (ADA) activities and neopterine levels during therapy in patients with pulmonary tuberculosis and community-acquired pneumonia Source: Annual Congress 2010 - What is new in the diagnosis of tuberculosis? Year: 2010
No evidence of altered PDE 4 or PDE 7 mRNA in asymptomatic asthma or stable COPD Source: ISSN=ISSN 1810-6838, ISBN=, page=71 Year: 2007